BridgeBio's Acoramidis Shows Promise in ATTR-CM Treatment

Acoramidis Demonstrates Efficacy in ATTR-CM Treatment

BridgeBio Pharma, Inc. has presented encouraging data from its Phase 3 ATTRibute-CM trial and open-label extension (OLE) study for Acoramidis, a potential treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). The results, shared at the European Society of Cardiology Congress 2023, highlight the drug's promising efficacy and safety profile 1

1

.

Improved Patient Outcomes

The study revealed that Acoramidis significantly improved key clinical outcomes in ATTR-CM patients. Participants who switched from placebo to Acoramidis in the OLE study showed a rapid increase in serum transthyretin (TTR) levels, reaching 98% of the levels observed in patients continuously treated with Acoramidis 2

2

. This increase in TTR levels is associated with improved cardiac function and reduced mortality risk in ATTR-CM patients.

Comparison with Existing Treatments

The data also suggested potential advantages of Acoramidis over tafamidis, a currently approved treatment for ATTR-CM. Patients who switched from tafamidis to Acoramidis experienced a substantial increase in serum TTR levels, with a median increase of 39% 3

3

. This finding indicates that Acoramidis may offer superior TTR stabilization compared to existing therapies.

Safety Profile and Tolerability

Throughout the study, Acoramidis demonstrated a favorable safety profile. The drug was well-tolerated by patients, with no significant safety concerns reported. This aspect is crucial for ATTR-CM patients, who often require long-term treatment management 1

1

.

Implications for ATTR-CM Treatment

The positive results from the Acoramidis trials have significant implications for ATTR-CM treatment. If approved, Acoramidis could provide a new, potentially more effective option for patients with this rare and life-threatening condition. The drug's ability to rapidly increase and maintain high TTR levels may translate to improved clinical outcomes and quality of life for ATTR-CM patients 2

2

.

Future Prospects and Regulatory Pathway

BridgeBio Pharma is progressing towards seeking regulatory approval for Acoramidis. The company has submitted a New Drug Application to the U.S. Food and Drug Administration and plans to file marketing authorization applications in other key markets. If approved, Acoramidis could potentially become a leading treatment option for ATTR-CM, addressing a significant unmet medical need in cardiovascular medicine 3

3

.